A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio(®)) in cardiac surgery: the REVAKI‐1 study

AIMS: Acute kidney injury (AKI) is a common and severe complication of cardiac surgery. There is no effective prevention or treatment. Sildenafil citrate (Revatio(®), Pfizer Inc.), a phosphodiesterase type 5 inhibitor, prevents post cardiac surgery AKI in pre‐clinical studies, however its use is con...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Clin Pharmacol
Autores principales: Ring, Arne, Morris, Tom, Wozniak, Marcin, Sullo, Nikol, Dott, William, Verheyden, Veerle, Kumar, Tracy, Brunskill, Nigel, Vaja, Rakesh, Murphy, Gavin J.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Trials
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5346869/
https://ncbi.nlm.nih.gov/pubmed/27779776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13162
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares